Company Summary: Plus Therapeutics, Inc.

Business Focus:
Plus Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies, primarily targeting rare and difficult-to-treat diseases, including cancer and neurological disorders.

Key Areas of Activity:

• Developing drug products utilizing advanced delivery technologies such as liposomes.
• Focused on translating research into approved products, especially in nanotechnology and liposomal drug delivery.
• Conducts research and operates in the pharmaceutical and biotechnology sectors with an emphasis on innovative therapeutics.

Corporate Details:

• Number of Employees: Not explicitly specified in the provided document.
• Number of Customers: Not specified in the provided excerpt.
• Revenue and Income: There is no mention of revenue, net income, or financial performance figures in the provided document.

Shareholder and Market Data:

• Market Capitalization: Approximately $8.2 million as of June 28, 2024, based on the stock closing price of $1.47 per share.
• Outstanding Shares: About 17 million shares of common stock issued and outstanding as of April 18, 2025.

Stock and Corporate Governance:

• Registered on Nasdaq Capital Market with the ticker symbol PSTV.
• The company is a smaller reporting company and an emerging growth company.

Additional Notes:

• The company has no publicly specify the number of clients or revenue figures within the available text.
• Focuses on clinical research, pharmaceutical research and development, and strategic investments in liposome and nanotechnology-based therapeutics.